A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma
Clinical trial NCT03314181 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03314181
- Sponsor
- AbbVie
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-04-02
- Primary completion
- 2031-05-01
- Enrollment
- 156
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.